Jane King engages in a compelling discussion with Collin Gage, the Founder and CEO of ARMR Sciences, about the escalating threat of synthetic opioids, particularly fentanyl. The conversation begins with Jane highlighting the alarming statistics surrounding fentanyl, noting that just one kilogram can potentially kill up to 500,000 people. Collin emphasizes that this crisis has evolved from a public health issue into a national security threat, with the potential to devastate entire cities.
Collin explains that ARMR Sciences is at the forefront of addressing this crisis with their innovative immunotherapy platform designed to neutralize synthetic drugs. Their flagship product, Armr-100, aims to train the body’s immune system to recognize and block fentanyl before it can cause harm. He elaborates on the science behind Armr-100, describing how it elicits an immune response that produces protective antibodies, effectively creating a biological shield against fentanyl and preventing it from attacking the brain.
“Our goal is to really create new, preventative, long-lasting countermeasures for these drug threats.” – 01:38
The discussion takes a poignant turn as Collin addresses the risks faced by first responders, who are often exposed to fentanyl without adequate protection. He draws a parallel to the past, when first responders lacked bulletproof vests, underscoring the urgent need for modern defenses against these new synthetic drug threats.
“We need to arm our first responders, our military, to the best of our ability.” – 02:54
Collin also shares insights into the support ARMR Sciences has received from the Department of Defense, which has funded much of their early-stage research. He reveals that their product has shown promising results, blocking up to 98% of fentanyl from reaching the brain and completely negating its addictive and analgesic effects. This is particularly significant for individuals struggling with opioid use disorder, as it provides them with a safer path to recovery.
As the segment concludes, Collin discusses ARMR Sciences’ plans for an initial public offering (IPO) in the near future, with a reserved stock ticker symbol, ARMR. He encourages listeners to stay tuned for updates on their progress as they continue their vital work in combating the fentanyl crisis.
This content is brought to you by ARMR Sciences.